Next-Generation Antibody Therapeutics Market Size Forecasted To Achieve $11.52 Billion By 2029 With Steady Growth

The Next-Generation Antibody Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Next-Generation Antibody Therapeutics Market Size and Projected Growth Rate?
The market size for next-generation antibody therapeutics has seen a swift expansion in recent years. The market, which is projected to rise from $6.82 billion in 2024 to $7.63 billion in 2025, has an anticipated compound annual growth rate (CAGR) of 11.8%. This growth within the historical timeframe can be credited to the success of monoclonal antibodies, the increasing incidence of chronic diseases, the approval of antibody-drug conjugates, and the enhancements in immunotherapy, gene therapy, and antibodies.

The market size for next-generation antibody therapeutics is predicted to experience fast expansion in the coming years. It is anticipated to rise to $11.52 billion in 2029, reflecting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth during the forecast period include the development of biosimilars, bispecific antibodies, and nanobodies, along with patient-targeted strategies, immunomodulatory antibodies, and extended usage in treating autoimmune diseases. Continuous production also significantly fuels this growth. The forecast period will also witness major trends such as advancements in the engineering of antibodies, the application of digital technologies in antibody design, collaborations within the industry, progression in drug delivery systems, and the utilization of real-world evidence in antibody development.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12678

What Are the Major Segments in the Next-Generation Antibody Therapeutics Market?
The next-generation antibody therapeutics market covered in this report is segmented -

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types
2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas
3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types
5) By Other Types: Nanobodies, Engineered Antibodies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Are The Driving Next-Generation Antibody Therapeutics Market Evolution?
The escalating rate of chronic health conditions is anticipated to fuel the progression of the next-generation antibody therapeutics market in the future. These chronic conditions are persistent issues lasting a year or more, requiring constant healthcare, limiting daily activities, or both. The innovative next-generation antibody therapeutics are created to provide more targeted treatment for those suffering from chronic diseases, thereby improving patient results. For illustration, the National Center for Biotechnology Information (NCBI), a branch of the U.S National Library of Medicine, projected in January 2023 that the number of people over 50 years of age with at least one chronic disease would escalate by 99.5%, reaching 142.66 million by 2050. Henceforth, the rising occurrence of chronic diseases is accelerating the expansion of the next-generation antibody therapeutics market.

Which Firms Dominate The Next-Generation Antibody Therapeutics Market Segments?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

What Trends Are Expected to Dominate the Next-Generation Antibody Therapeutics Market in the Next 5 Years?
The upward trend of technological innovations is playing an influential role in the field of next-generation antibody therapeutics. Many prominent companies within this market segment are adopting technological advancements like the Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. These novel innovations seek to heighten protein identification and characterization, paving the way for treatments that are more targeted and efficient. Aiming to bolster therapeutic profiles, cut operational costs, and tackle intricate diseases with increased precision, these advancements hold great promise. MIPSA is a pivotal technology that arranges protein molecules into ordered structures, enhancing their analysis and quantification capabilities. This refinement leads to sensitivity and precision in protein detection, making it valuable for research and diagnostics. In January 2024, an example of this application was seen when Infinity Bio, Inc., a US biotechnology firm, debuted a next-generation antibody profiling platform incorporating MIPSA technology. This provided a high-throughput, cost-effective solution for analyzing immune responses, with the goals of improving disease comprehension and personalizing treatment strategies.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Is The Largest Region In The Next-Generation Antibody Therapeutics Market?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Next-Generation Antibody Therapeutics Market?
2. What is the CAGR expected in the Next-Generation Antibody Therapeutics Market?
3. What Are the Key Innovations Transforming the Next-Generation Antibody Therapeutics Industry?
4. Which Region Is Leading the Next-Generation Antibody Therapeutics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.